| Trial ID: | L2763 |
| Source ID: | NCT05324462
|
| Associated Drug: |
Ideglira
|
| Title: |
Glycaemic Control and Other Clinical Parameters in Adult Type 2 Diabetes Patients on Basal Insulin Initiating Treatment With IDegLira in Routine Clinical Practice in Colombia
|
| Acronym: |
SPIRIT
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: IDegLira
|
| Outcome Measures: |
Primary: Change in local laboratory measured Glycated Haemoglobin A1c (HbA1c), Percentage point, From baseline (week 0) to end of study (week 26 plus/minus 6 weeks) after IDegLira initiation | Secondary: Change in absolute body weight, Kilogram (kg), From baseline (week 0) to end of study (week 26 plus/minus 6 weeks) after IDegLira initiation|Comparison between the daily dose of basal insulin and IDegLira, Units/day, From baseline (week 0) to end of study (week 26 plus/minus 6 weeks) after IDegLira initiation
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
175
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2022-03-22
|
| Completion Date: |
2022-07-15
|
| Results First Posted: |
|
| Last Update Posted: |
2022-11-09
|
| Locations: |
Novo Nordisk Investigational Site, Medellín, Antioquia, Colombia|Novo Nordisk Investigational Site, Barranquilla, Atlantico, Colombia|Novo Nordisk Investigational Site, Bogotá, Bogota DC, Colombia|Novo Nordisk Investigational Site, Montería, Cordoba, Colombia|Novo Nordisk Investigational Site, Cúcuta, Norte De Santander, Colombia|Novo Nordisk Investigational Site, Bucaramanga, Santander, Colombia
|
| URL: |
https://clinicaltrials.gov/show/NCT05324462
|
